Jci_page_head_homepage_01 Jci_page_head_homepage_02
Paul A. Finney, Maria G. Belvisi, Louise E. Donnelly, Tsu-Tshen Chuang, Judith C.W. Mak, Carol Scorer, Peter J. Barnes, Ian M. Adcock, Mark A. Giembycz
Published in Volume 106, Issue 1
J Clin Invest. 2000; 106(1):125–135 doi:10.1172/JCI8374
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 2

Effect of chronic treatment of rats with albuterol (ad) or PGE2 (e and f) on lung function in anesthetized rats. Animals were given albuterol, PGE2 (open bars; both 40 μg/kg/h) or vehicle (filled bars) for 7 days and then instrumented for the measurement of lung function. ACh (500 μg/kg intravenously) was administered and the maximum increase in overflow pressure was measured. When baseline lung function was reestablished, albuterol (Alb; 100 μg/kg; a and f), PGE2 (PG; 300 μg/kg; b and e), forskolin (F; 300 μg/kg; c), or IBMX (300 μg/kg; d) was given intravenously, and 5 minutes later, ACh was administered again and any change in overflow pressure was noted. Each bar represents the mean ± SEM of four independent determinations. AP < 0.05, significant protection of ACh-induced bronchoconstriction.